Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb;36(2):580-582.
doi: 10.1038/s41375-021-01386-z. Epub 2021 Aug 18.

Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group

Carla Damaschin  1   2 , Helen Goergen  1   2 , Stefanie Kreissl  1   2 , Annette Plütschow  1   2 , Frank Breywisch  3 , Stephan Mathas  4 , Julia Meissner  5 , Martin Sökler  6 , Max S Topp  7 , Vladan Vucinic  8 , Andreas Zimmermann  9 , Bastian von Tresckow  2   10 , Michael Fuchs  1   2 , Andreas Engert  1   2 , Peter Borchmann  1   2 , Dennis A Eichenauer  11   12
Affiliations

Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group

Carla Damaschin et al. Leukemia. 2022 Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

BvT is an advisor or consultant for Amgen, BMS/Celgene, Novartis, Pentixafarm, Pfizer, Takeda, Merck Sharp & Dohme, and Gilead Kite; has received honoraria from Novartis, Roche Pharma AG, Takeda, and Merck Sharp & Dohme; reports research funding from Novartis (Inst), Merck Sharp & Dohme (Inst), and Takeda (Inst); and reports travel support from AbbVie, AstraZeneca, KiteGilead, Merck Sharp & Dohme, Takeda, and Novartis. AZ has received honoraria from Takeda; and reports travel grants from Takeda. All other authors report no potential conflicts of interest.

Figures

Fig. 1
Fig. 1. Outcomes of patients treated with BrECAPP and BrECADD.
A) Progression-free survival after treatment with BrECAPP and BrECADD; B) Overall survival after treatment with BrECAPP and BrECADD.
See this image and copyright information in PMC

References

    1. Engert A, Haverkamp H, Kobe C, Markova J, Renner C, Ho A, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012;379:1791–9. doi: 10.1016/S0140-6736(11)61940-5. - DOI - PubMed
    1. Borchmann P, Goergen H, Kobe C, Lohri A, Greil R, Eichenauer DA, et al. PET-guided treatment in patients with advanced-stage Hodgkin’s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet. 2017. 10.1016/S0140-6736(17)32134-7. - PubMed
    1. Eichenauer DA, Becker I, Monsef I, Chadwick N, de Sanctis V, Federico M, et al. Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trials. Haematologica. 2017;102:1748–57. doi: 10.3324/haematol.2017.167478. - DOI - PMC - PubMed
    1. Behringer K, Mueller H, Goergen H, Thielen I, Eibl AD, Stumpf V, et al. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. J Clin Oncol. 2013;31:231–9. doi: 10.1200/JCO.2012.44.3721. - DOI - PubMed
    1. Eichenauer DA, Plutschow A, Kreissl S, Sokler M, Hellmuth JC, Meissner J, et al. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin’s lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group. Lancet Oncol. 2017;18:1680–7. doi: 10.1016/S1470-2045(17)30696-4. - DOI - PubMed

Publication types

MeSH terms